Grapes Could Help Prevent Age-Related Blindness

U.S. study finds grapes could help prevent age-related blindness
To view it click here:
http://www.freshfruitportal.com/2012/01/12/u-s-study-finds-grapes-could-help-prevent-age-related-blindness/

http://www.freshfruitportal.com

Food for Your Macula

http://thestar.com.my/health/story.asp?file=/2011/10/30/health/9780377&sec=health

Can Avastin Use in Macular Degenration Cause Blindness

http://thechart.blogs.cnn.com/2011/10/19/can-avastin-use-in-macular-degenration-cause-blindness/

 

New Device Developed to Help Prevent AMD

http://topnews.net.nz/content/213456-new-device-developed-prevent-amd

Visual Impairments Specialist
Westminster Elementary School
http://lee.ebrschools.org/kathynicholslee
http://www.kathyskids.org
http://teacherweb.com/LA/RobertELeeHigh/MrsMichael/t.aspx
http://mskathyskids.blogspot.com

Possible Cure for ARMD Blindness

http://www.starcitynews.com/a-possible-cure-for-old-age-blindness-is-now-in-trials/1637

Visual Impairments Specialist
Westminster Elementary School
http://lee.ebrschools.org/kathynicholslee
http://www.kathyskids.org
http://teacherweb.com/LA/RobertELeeHigh/MrsMichael/t.aspx
http://mskathyskids.blogspot.com

Visual Impairments Specialist
W E School
http://lee.ebrschools.org/kathynicholslee
http://www.kathyskids.org
http://teacherweb.com/LA/RobertELeeHigh/MrsMichael/t.aspx
http://mskathyskids.blogspot.com

Study Claims Vitamin A Pill Could Stop Blindness in Old Age

http://uktodaynews.com/9595/us-study-claims-that-vitamin-a-pill-could-stop-blindness-in-old-age/

Article from Xconomy recommended by kathy: Otonomy Gets $38.5M, Avalon Helps Restart Drug for Age-Related Blindness, Accumetrics Heads Toward Profitability, & More San Diego Life Sciences News

Hi MsKathysKids,
Your friend, kathy, thought you'd be interested in this article from Xconomy:
Otonomy Gets $38.5M, Avalon Helps Restart Drug for Age-Related Blindness, Accumetrics Heads Toward Profitability, & More San Diego Life Sciences News
Posted by Bruce V. Bigelow on September 2, 2010 (7:40 am).
Here are kathy's remarks:
N/A
If the article link above doesn't work, try copying this url and pasting it into your browser:
http://www.xconomy.com/san-diego/2010/09/02/otonomy-gets-38-5m-avalon-helps-restart-drug-for-age-related-blindness-accumetrics-heads-toward-profitability-more-san-diego-life-sciences-news/
For more of the latest biz/tech news, visit Xconomy at http://www.xconomy.com/.

Otonomy Gets $38.5M, Avalon Helps Restart Drug for Age-Related Blindness, Accumetrics Heads Toward Profitability, & More San Diego Life Sciences News

http://www.xconomy.com/san-diego/2010/09/02/otonomy-gets-38-5m-avalon-helps-restart-drug-for-age-related-blindness-accumetrics-heads-toward-profitability-more-san-diego-life-sciences-news/

Hadassah has vision for treating blindness for the aging

Your friend, Ms.Kathy, has sent you an article from JPost.

Article: Hadassah has vision for treating blindness for the aging

Click here to view the entire article:
http://www.jpost.com/servlet/Satellite?pagename=JPost%2FJPArticle%2FShowFull&cid=1254756249218

AOL Users click here to view the article:
<A HREF="http://www.jpost.com/servlet/Satellite?pagename=JPost%2FJPArticle%2FShowFull&cid=1254756249218">http://www.jpost.com/servlet/Satellite?pagename=JPost%2FJPArticle%2FShowFull&cid=1254756249218</A>

Don't miss out on any of the important breaking news stories and in-depth analysis about Israel you can only get from JPost.For more news updates, go to http://www.jpost.com

The 'Holy Grail' of Ophthalmic Devices

The 'Holy Grail' of Ophthalmic Devices

Believe it or not, the bionic eye is more fact than fiction. A device called Argus II is currently being developed by engineers at five U.S. Department of Energy laboratories and four universities. The high-density microelectronic-tissue hybrid device aims to restore sight to people blinded by diseases such as age-related macular degeneration and retinitis pigmentosa.

To view the entire article click here

Potentia Pharmaceuticals' POT-4 Drug Candidate For Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial

Dear Ms. Kathy's Blog Readers,

Ms. Kathy wants to share this Medical News Today. Ms. Kathy saw this article on the Medical News Today website and thought you might be interested in it:

************************************************************

Potentia Pharmaceuticals' POT-4 Drug Candidate For Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial

Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced that it successfully completed its Phase I ASaP (Assessment of Safety of Intravitreal POT-4 Therapy for Patients with Neovascular Age-Related Macular Degeneration) clinical trial for the company's leading drug candidate, POT-4...

To read the full article, please go to:
http://www.medicalnewstoday.com/articles/148725.php

************************************************************

Ms. Kathy wants to share this Medical News Today article with you

Dear Ms. Kathy's Kids Blog,

Ms. Kathy saw this a_rticle on the Medical News Today website and thought you might be interested in it:

-- Comments --
Another reason to QUIT SMOKING, HUNNEE!

************************************************************

Tufts Medical Center Researchers Create A New Predictive Model For Age-related Macular Degeneration (AMD)

Researchers at Tufts Medical Center have created a formula for predicting how likely it is that individuals with certain genetic profiles and lifestyle behaviors will develop advanced Age-related Macular Degeneration (AMD), a potentially blinding condition that currently affects an estimated two million older Americans and is increasing dramatically as the population ages...

To read the full article, please go to:
http://www.medicalnewstoday.com/articles/147342.php

************************************************************

Color Choice

My favorite color is blue. You would think so with the all the blue on this blog, but because I like blue is not the whole story. I have a medium dark color as a background with light writing because there are eye conditions for which that arrangement is more comfortable.

For instance for a person with ocular albinism a white background from a computer screen may give off too much light or glare making the eyes tire more quickly and sometimes even washing out the print. Persons with aniridia, Stargardt's syndrome, macular degeneration and cataracts may have the same problem.That is why I advise teachers who have students with these conditions to consider these problems when creating PowerPoint presentations, Smart Board activities, directed browsing activities, over head projections and the like.

I also chose blue because with most colorblindness, blue is most often the color that can be detected. Total colorblindness is very rare. Colorblindness may also accompany some other conditions such as those above and retinitis pigmentosa.

From The Sunday Times April 19, 2009 Blind to be cured with stem cells Sarah-Kate Templeton, Health Editor BRITISH scientists have developed the world's first stem cell therapy to cure the most common cause of blindness. Surgeons predict it will become a routine, one-hour procedure that will be generally available in six or seven years' time. The treatment involves replacing a layer of degenerated cells with new ones created from embryonic stem cells. It was pioneered by scientists and surgeons from the Institute of Ophthalmology at University College London and Moorfields eye hospital. This week Pfizer, the world's largest pharmaceutical research company, will announce its financial backing to bring the therapy to patients. The treatment will tackle age-related macular degeneration (AMD), the most common cause of blindness. It affects more than 500,000 Britons and the number is forecast to increase significantly as people live longer. The disease involves the loss of eye cells. Under the new treatment, embryonic stem cells are transformed into replicas of the missing cells. They are then placed on an artificial membrane which is inserted in the back of the retina. Tom Bremridge, chief executive of the Macular Disease Society, said: "This is a huge step forward for patients. We are extremely pleased that the big guns have become involved, because, once this treatment is validated, it will be made available to a huge volume of patients." Embryonic stem cells have the ability to develop into all types of body tissue. Their use is controversial, however, because it involves the destruction of human embryos. Laboratory trials completed by the British team have demonstrated that stem cells can prevent blindness in rats with a similar disease to AMD. They have also successfully tested elements of the technology in pigs. The team is led by Professor Pete Coffey, director of the London Project to Cure Blindness, working alongside Lyndon da Cruz, a surgeon at Moorfields. Coffey said the treatment would take "less than an hour, so it really could be considered as an outpatient procedure. We are trying to get it out as a common therapy". He welcomed Pfizer's agreement to manufacture the membranes, saying: "This is a major development because of the size of the partner. We need a big pharmaceutical company to scale it up. "We have nearly 14m people within Europe with AMD. This will ensure that the therapy gets through to clinical trials in a safe and effective manner." Professor Peng Khaw, director of the Biomedical Research Centre at Moorfields and the UCL Institute of Ophthalmology, added: "This shows that stem cell therapy is coming of age. It offers great hope for many sufferers around the world who cannot be treated with conventional treatment." He added: "All my patients say to me is, 'When will this stem cell treatment be ready? I want it now'." Pfizer's role would be crucial in bringing production of the membranes to an industrial level. The team is applying for regulatory approval for trials from the Medicines and Healthcare products Regulatory Agency, the Human Tissue Authority and the gene therapy advisory committee. The clinical trial, due within two years, is expected to be the second in the world to use embryonic stem cells on humans. The first, on patients with spinal cord injuries, will start this year in America.